0001493152-23-024402.txt : 20230713 0001493152-23-024402.hdr.sgml : 20230713 20230713092506 ACCESSION NUMBER: 0001493152-23-024402 CONFORMED SUBMISSION TYPE: D PUBLIC DOCUMENT COUNT: 1 ITEM INFORMATION: 06b FILED AS OF DATE: 20230713 DATE AS OF CHANGE: 20230713 EFFECTIVENESS DATE: 20230713 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Oncotelic Therapeutics, Inc. CENTRAL INDEX KEY: 0000908259 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 133679168 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: D SEC ACT: 1933 Act SEC FILE NUMBER: 021-486718 FILM NUMBER: 231085865 BUSINESS ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 BUSINESS PHONE: 650-635-7000 MAIL ADDRESS: STREET 1: 29397 AGOURA RD. STREET 2: #107 CITY: AGUORA HILLS STATE: CA ZIP: 91301 FORMER COMPANY: FORMER CONFORMED NAME: MATEON THERAPEUTICS INC DATE OF NAME CHANGE: 20160613 FORMER COMPANY: FORMER CONFORMED NAME: OXIGENE INC DATE OF NAME CHANGE: 19930628 D 1 primary_doc.xml X0708 D LIVE 0000908259 Oncotelic Therapeutics, Inc. 29397 AGOURA ROAD, SUITE 107 AGOURA HILLS CA CALIFORNIA 91301 650-635-7000 DELAWARE Mateon Therapeutics, Inc. OXiGENE, Inc. MATEON THERAPEUTICS INC OXIGENE INC Corporation true Vuong Trieu 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer Director The above is the Chief Executive Officer of Oncotelic and the Chief Executive Officer and President of EdgePoint AI, Inc. Amit Shah 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer The above is the Chief Financial Officer of Oncotelic and of EdgePoint AI, Inc. Anthony Maida 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer The above is the Chief Medical Officer - Translation Officer of Oncotelic Seymour Fein 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer The above is the Chief Regulatory Officer of Oncotelic Saran Saund 29397 Agoura Road, Suite 107 Agoura Hills CA CALIFORNIA 91301 Executive Officer The above is the Chief Business Officer of Oncotelic and Edgepoint AI Biotechnology Decline to Disclose 06b false true false true true true true Offering of units consisting of (i) Oncotelic notes, which are convertible into Oncotelic common stock, and (ii) warrants to purchase Oncotelic common stock. false 25000 None 43520 JH Darbie & Co,. Inc. None 48 WALL STREET SUITE 1206 NEW YORK NY NEW YORK 10005 All States false 5000000 0 5000000 true 0 15 650000 true 0 Oncotelic will pay JH Darbie & Co,. Inc. a sales commission equal to 10% of the gross amount of the proceeds received for the sale of all of the units. The above amount represents $500,000.00 for sales commissions and $150,000.00 for expenses. 0 false Oncotelic Therapeutics, Inc. /s/ Vuong Trieu Vuong Trieu CEO 2023-07-13